Sarepta’s Elevidys Sales Surge, But Next-Gen DMD Drug Platform Discontinued
Safety Scuttles SRP-5051, All Other PPMO Assets
Q3 sales of DMD gene therapy Elevidys beat forecasts, but the company declined to raise Q4 and 2025 guidance. It plans to file a second gene therapy with the US FDA next year.
